Displaying 2661 - 2680 of 4735
1502002 Informal Interpretation
FTC Submits Fiscal Year 2016 Budget Request, Performance Plan, and Fiscal Year 2014 Performance Report to Congress
Announcement of Second Public Workshop on Examining Health Care Competition
1501004 Informal Interpretation
1501005 Informal Interpretation
FTC Puts Conditions on Sun Pharmaceutical’s Proposed Acquisition of Ranbaxy
1501003 Informal Interpretation
FTC Announces Schedule for Reviewing Regulations
FTC Requires Albertsons and Safeway to Sell 168 Stores as a Condition of Merger
FTC, DOJ to Host Second Public Workshop on Examining U.S. Health Care Competition
FTC Approves Final Order Preserving Future Competition in the Market for Drug-coated Balloon Catheters Used to Treat Peripheral Artery Disease
Medtronic, Inc. and Covidien plc, In the Matter of
Global medical technology company Medtronic, Inc. agreed to divest the drug-coated balloon catheter business of Ireland-based medical products company Covidien plc, in order to settle FTC charges that its $42.9 billion acquisition of Covidien would likely be anticompetitive. Under the FTC’s proposed settlement, Medtronic will sell the drug-coated balloon catheter business to a Colorado-based medical device company, The Spectranetics Corporation. According to the FTC’s complaint, both Medtronic and Covidien are developing drug-coated balloon catheters to compete with C.R. Bard, Inc., which currently is the only company that supplies these products, used to treat peripheral artery disease, in the U.S. market. Medtronic and Covidien are the only companies with products in clinical trials in the Food and Drug Administration’s approval process, which makes it unlikely that other competitors could enter the market in time to counteract the effects of the merger.
FTC Approves Final Order Preserving Competition in the Market for Nicotine Patches
Displaying 2661 - 2680 of 4735